AI Article Synopsis
- Unresectable pancreatic cancer can lead to duodenal blockages, requiring surgical intervention.
- Two case studies are presented where patients underwent duodenal bypass surgeries and began chemotherapy treatment afterward.
- Both patients experienced quick recovery, improved health status, and weight gain, indicating that duodenum bypass is preferable for maintaining stable digestion and facilitating early chemotherapy.
Article Abstract
Unresectable(UR)pancreatic cancer often causes duodenal obstruction. Case 1: A 58-year-old man was diagnosed with UR pancreatic cancer with obstruction of the 3rd duodenal portion. A duodenum 2nd portion jejunum bypass was performed, and FOLFIRINOX was introduced and continued over 6 months. Case 2: A 74-year-old man was diagnosed with UR pancreatic cancer with obstruction of the duodenum near the Treitz ligament. A duodenum 3rd portion jejunum bypass was performed, and gemcitabine plus nab-paclitaxel was introduced. After 8 courses of GN, adjuvant surgery was performed. Both patients resumed oral intake within a few days after bypass, their performance statuses(PS)were improved, and their body weights increased. Because a duodenal jejunum bypass is more physiological than a gastro-jejunum bypass and duodenal stent, stable ingestion is enabled, and they are stable enough for early initiation of chemotherapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cancer-Associated Fibroblast-Secreted Exosomes Regulate Macrophage Polarization in Pancreatic Cancer via the NOD1 Pathway.
J Biochem Mol Toxicol
January 2025
Department of Pathology and Pathophysiology, School of Medicine, Jinan University, Guangzhou, China.
Metastasis is a major cause of poor prognosis of pancreatic cancer. Exosomes (Exos) regulate cancer progression by modulating macrophage polarization. This study aimed to investigate the effects of cancer-associated fibroblast (CAF)-released Exos on macrophage polarization in pancreatic cancer and the molecular mechanisms.
View Article and Find Full Text PDFASO Visual Abstract: Defining and Predicting Early Recurrence for Optimal Treatment Strategies in Intraductal Papillary Mucinous Neoplasm-Derived Pancreatic Cancer--An International Multicenter Study.
Ann Surg Oncol
January 2025
Department of Surgery, Regional Academic Cancer Center Utrecht, UMC Utrecht Cancer Center and St. Antonius Hospital Nieuwegein, Utrecht, The Netherlands.
Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC.
BMC Surg
January 2025
Department of General, Visceral and Transplantation Surgery, LMU University Hospital Munich, LMU Munich, Munich, Germany.
Background: Pancreatic ductal adenocarcinoma (PDAC) typically occurs in an older patient population. Yet, early-onset pancreatic cancer (EOPC) has one of the fastest growing incidence rates. This study investigated the influence of age and tumor location on postoperative morbidity and mortality in a large, real-world dataset.
View Article and Find Full Text PDFSIGLEC11 promotes M2 macrophage polarization through AKT-mTOR signaling and facilitates the progression of gastric cancer.
J Immunother Cancer
January 2025
Department of General Surgery, Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Background: Sialic acid-binding immunoglobulin-like lectins (SIGLECs) are widely expressed on immune cell surfaces, play an important role in maintaining immune homeostasis and regulating inflammatory responses, and are increasingly emerging as potential targets for tumor immunotherapy. However, the expression profile and crucial role of SIGLEC11 in gastric cancer (GC) remain unclear. This study aimed to elucidate the prognostic relevance of SIGLEC11 expression and its role in the immune microenvironment in patients with GC.
View Article and Find Full Text PDFResponse to letter to the editor: "A striking elevation of CA19-9 after preoperative therapy negates prognostic benefit from radical surgery in resectable or borderline resectable pancreatic cancer".
Surgery
January 2025
Department of Surgery, Osaka Internationa Cancer Institute, Osaka, Japan.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!